Letairis (ambrisentan) Disease Interactions
There are 4 disease interactions with Letairis (ambrisentan):
Endothelin receptor antagonists (Includes Letairis) ↔ hepatotoxicity/liver impairment
Severe Potential Hazard, Moderate plausibility. Applies to: Liver Disease
Endothelin receptor antagonists (ERAs) have been associated with aminotransferase elevations, hepatotoxicity, and cases of liver failure. Hepatic function should be assessed before treatment initiation and closely monitored during treatment. Therapy should be discontinued if aminotransferase elevations are accompanied by increases in bilirubin, or clinical symptoms of hepatotoxicity such as nausea, vomiting, fever, abdominal pain or jaundice. Treatment should be avoided in patients with elevated aminotransferases at baseline as monitoring for hepatotoxicity may be more difficult. In general, the use of ERAs is not recommended for patients with moderate to severe hepatic impairment.
Ambrisentan (Includes Letairis) ↔ renal impairment
Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction
There is no information on the exposure to ambrisentan in patients with severe renal impairment. Additionally, the impact of hemodialysis on the disposition of ambrisentan has not been studied, hence caution is advised. No dosage adjustment is required in patients with mild or moderate renal impairment.
Endothelin receptor antagonists (Includes Letairis) ↔ anemia
Moderate Potential Hazard, Moderate plausibility. Applies to: Anemia
Clinical studies have shown that most endothelin receptor antagonists decrease hemoglobin concentration and hematocrit levels. There are some postmarketing reports of anemia cases which needed blood transfusion. Hemoglobin and hematocrit levels should be measured prior to treatment initiation and should be monitored periodically thereafter. Initiation of therapy is not recommended in patients with clinically significant anemia.
Endothelin receptor antagonists (Includes Letairis) ↔ fluid retention
Moderate Potential Hazard, Moderate plausibility. Applies to: Congestive Heart Failure
Peripheral edema and fluid retention are known clinical consequences of pulmonary hypertension and also known effects of endothelin receptor antagonists. Caution and monitoring is recommended if these agents are used in patients with underlying left ventricular dysfunction or underlying heart failure, as they have an increased risk for developing significant fluid retention that may need treatment or require discontinuation.
Letairis (ambrisentan) drug interactions
There are 132 drug interactions with Letairis (ambrisentan)
More about Letairis (ambrisentan)
- Letairis Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Compare Alternatives
- Pricing & Coupons
- En Español
- 10 Reviews
- Drug class: agents for pulmonary hypertension
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.